Neurotrope, Inc.
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | — | — | — | $32.5M | $22.4M | $13.7M |
| Net income | −$15.1M | −$11.0M | −$12.6M | −$12.9M | −$9.4M | −$9.3M |
| Total assets | $17.9M | $29.5M | $16.4M | $26.0M | $12.8M | $8.2M |
| Total liabilities | — | — | — | — | — | — |
| Equity | $17.4M | $26.5M | $14.9M | $23.6M | −$23,419 | −$11.7M |
| EPS (diluted) | — | — | — | — | — | — |
| Shares out. | 12.9M | 7.9M | 7.4M | 49.2M | 26.8M | 21.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −86.9%
- Return on assets
- −84.6%
- Return on capital (ROCE)
- —
- Liabilities / assets
- —
- Debt / equity
- —
- Book value / share
- $1.35
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Accruals / assets
- −18.1%clean
- Piotroski F-Score
- 2/6weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 1 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Apr 1, 2014
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Other material eventDec 7, 2020
- Shareholder voteNov 25, 2020
- Other material eventNov 24, 2020
- Other material eventNov 20, 2020
- Other material eventSep 30, 2020
- Entered a material agreementSep 30, 2020
- Entered a material agreementJul 29, 2020
- Other material eventJul 24, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AAMENDMENT NO. 1 TO SCHEDULE 13GJan 29, 2021
- 8-KFORM 8-KDec 7, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 4OWNERSHIP DOCUMENTDec 3, 2020
- 25-NSEDec 2, 2020
- 4OWNERSHIP DOCUMENTNov 27, 2020
- 4OWNERSHIP DOCUMENTNov 27, 2020
- 4OWNERSHIP DOCUMENTNov 27, 2020